BIO recognizes the unique needs of emerging companies. From advocating for pro-innovation tax policies to encouraging an economic and policy environment to foster investment, we focus on critical issues affecting smaller companies and build programs to enhance their development.
- Improving market quality for small public companies, like working with Nasdaq to advocate for increased transparency around short selling positions and advocating for SEC oversight of proxy advisory firms.
- Advocating for tax code reforms that incentivize investment in pre-revenue innovators, including the Jobs Act and Sarbanes-Oxley (SOX) Section 404(b).
- Engaging the Committee on Foreign Investment in the U.S. (CFIUS) in it's rulemaking process to avoid an undue impact on the biotechnology sector's ability to enter into global research partnerships and attract foreign investments.
BIO recognizes the need for capital and collaboration faced by startups. Therefore we host more than a dozen events throughout the year to help small biotechs connect with potential investors, licensors, and partners. BIO members receive discounts on registration, presentation, and exhibition fees at BIO events.
“Simply put - BIO represents the community of leadership and innovation in biotechnology. This role gives voice to initiatives critical to the success of our industry: from workforce diversity to regulatory and financial developments. As a small biotech, having the connections and support to navigate these resources is incredibly important for both our company and for the industry as a whole."
Chief Executive Officer